Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105,841,018
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
1,859,470
-
Shares change
-
-31,756
-
Total reported value, excl. options
-
$17,100,000
-
Value change
-
-$844,204
-
Put/Call ratio
-
59%
-
Number of buys
-
18
-
Number of sells
-
-11
-
Price
-
$9.16
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q3 2021
43 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,859,470 shares
of 105,841,018 outstanding shares and own 1.76% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (651,283 shares), BlackRock Inc. (252,838 shares), MORGAN STANLEY (184,868 shares), GEODE CAPITAL MANAGEMENT, LLC (133,801 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (112,866 shares), BANK OF MONTREAL /CAN/ (110,192 shares), Equitable Holdings, Inc. (100,000 shares), BANK OF AMERICA CORP /DE/ (43,891 shares), CITADEL ADVISORS LLC (42,489 shares), and STATE STREET CORP (37,468 shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.